Article | May 30, 2023

Causing A Stir In Cell Therapy Scale-Up

T cells GettyImages-956478348

Many manufacturers are leveraging bioreactors when scaling up their processes to meet the automation and scalability needs of large-scale manufacturing and successful adoption of cell therapies. Some of the benefits of closed, automated bioreactors is that they reduce the likelihood of human error as well as shortening manufacturing times and costs. However, manufacturers must consider the culture medium used when scaling up their process. Successful workflows at larger scales require a culture medium that is designed to support high-density T cell culture.

Delve into how dynamic bioreactors may offer performance enhancements over traditional static types and the methods manufacturers can apply to further optimize their bioreactor performance.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene

Thermo Fisher Scientific Bioproduction